Home・Akciju saraksts・Hims & Hers Health Inc

Hims & Hers Health Inc

Atvērts

SektorsPatēriņa aizsardzības

32.07 4.09

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

30.24

Max

31.73

Galvenie mērījumi
By Trading Economics
Ienākumi	-113M -92M
Pārdošana	-9.7M 608M
P/E Sektora vidējais	57.137 33.699
EPS	-0.19
Peļņas marža	-15.148
Darbinieki	2,442
EBITDA	-107M -80M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	-3.05% downside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 10. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	266M 7B
Iepriekšējā atvēršanas cena	27.98
Iepriekšējā slēgšanas cena	32.07

Ziņu noskaņojums

By Acuity

50%

52 / 130 Rangs Consumer defensive

Hims & Hers Health Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. aug. 23:41 UTC

News

Hims & Hers Health shares are higher in after-market trading, following positive growth insights despite facing a lawsuit from the Federal Trade Commission.

2026. g. 31. jūl. 19:36 UTC

Social Media

News

Hims & Hers Health Inc is trading higher amid social media discussions about potential undervaluation, despite facing a lawsuit over user health data practices.

2026. g. 30. jūl. 20:11 UTC

Hims & Hers Health Inc shares are higher today amid high trading volume. Broader economic data showed mixed signals, contributing to market volatility.

2026. g. 29. jūl. 23:16 UTC

Social Media

News

Hims & Hers Health shares declined in after-market trading amid legal challenges from the FTC over alleged privacy violations and a securities fraud investigation.

2026. g. 28. jūl. 23:41 UTC

Hims & Hers Health shares declined in after-market trading, remaining near the lower end of their one-month range amid broader market pressures from Asian tech losses.

2026. g. 27. jūl. 20:03 UTC

News

Social Media

Hims & Hers Health shares rise amid FDA committee's endorsement of peptides, seen as a significant step toward market access for treatments.

2026. g. 24. jūl. 23:16 UTC

Social Media

Hims & Hers Health Inc. shares rose after-hours following positive votes from an FDA/HHS panel on six peptides, with a final decision expected in up to 12 months.

2026. g. 23. jūl. 23:26 UTC

News

Hims & Hers Health Inc shares are higher after an FDA advisory panel recommended easing restrictions on a popular peptide and Canaccord reiterated a Buy rating.

2026. g. 22. jūl. 23:16 UTC

News

Hims & Hers Health shares declined to about $31.66 after mixed options sentiment, with calls outpacing puts amid lighter trading volume.

2026. g. 21. jūl. 17:31 UTC

News

Hims & Hers Health Inc shares are declining amid an investigation into potential wrongdoing and concerns over FDA approval of key peptides.

2026. g. 20. jūl. 18:37 UTC

News

Hims & Hers Health Inc. is trading higher amid broader market dynamics, despite earlier pulling back from a session high.

Salīdzinājums

Cenas izmaiņa

Hims & Hers Health Inc Prognoze

Cenas mērķis

By TipRanks

-3.05% uz leju

Prognoze 12 mēnešiem

Vidējais 29.88 USD -3.05%

Augstākais 40 USD

Zemākais 21 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Hims & Hers Health Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

13 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 13 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Hims & Hers Health Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

52 / 130 Rangs Patēriņa aizsardzības

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.